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Abstract: Ellipticines have well documented anticancer activity, in particular with substitution at
the 1-, 2-, 6- and 9-positions. However, due to limitations in synthesis and coherent screening
methodology the full SAR profile of this anticancer class has not yet been achieved. In order to
address this shortfall, we have set out to explore the anticancer activity of this potent natural product
by substitution. We currently describe the synthesis of novel 11-substituted ellipticines with two
specific derivatives showing potency and diverging cellular growth effects.
Keywords: ellipticine; anticancer; heterocyclic chemistry; indole; NCI screen; topoisomerase II
1. Introduction
Cancer is a collection of diseases defined by the proliferation of cells in an unregulated and
inappropriate manner leading to tumours and eventual mortality. Within this broad definition it is
evident that the control of cell growth is a key mechanism as cell growth can be restricted, proliferation
can be stopped and cells can be killed by multiple anticancer agents, one of which (ellipticine) is
explored further here [1].
Ellipticine 1 (5,11-dimethyl-6H-pyrido [4,3-b]carbazole, Figure 1) is a natural product which
was isolated in 1959 from a small tropical evergreen tree (Ochrosia elliptica) by Goodwin et al. [2].
The extract also contained a number of other alkaloids, including the related 9-methoxyellipticine
2. Since its isolation, the planar tetracyclic structure of ellipticine has been the focus of extensive
chemical and pharmacological research [3]. Over the last 60 years, ellipticine and its derivatives
have been identified with potent anticancer activity and been subject to clinical trials. Celiptium
(9-hydroxy-N-methylellipticinium acetate) 3 and 9-hydroxyellipticine 4 both progressed to phase II
clinical trials though these were subsequently discontinued due to side effects and efficacy [4–7].





Figure 1. Structures of Ellipticine 1 and related anticancer agents. 
The mechanisms by which ellipticine exerts its anticancer activity are particularly diverse. These 
include topoisomerase II inhibition with associated DNA intercalation, well established in the 
literature and clinically relevant [8–10]. Cytotoxic ellipticine metabolites via biooxidation at a number 
of positions on the tetracycle and subsequent adduct formation have also been identified as 
responsible for some of the effects [11]. Recently, ellipticines have been described to interact with 
kinases such as c-Kit, AKT and CK2, and to influence the p53 tumour suppressor, all of which have 
key roles in cell growth and progression [12–14]. Ellipticines have also been discovered to disrupt 
RNA polymerase I transcription and stabilize pharmaceutically relevant G-quadruplexes and so 
there is significant and continued interest in the biological effects of this compound class [15,16].  
It is therefore evident that ellipticine and its derivatives exhibit multimodal activity with simple 
substitutions on this template eliciting diverse effects. Despite their potency, there has been little 
exploration of the functional space in this natural product outside of the 1-, 2-, 6- and 9-positions in 
order to answer fundamental questions in pharmacology and effect on cells. A programme of 
research has been initiated in this group in order to evaluate the effect of novel substitution patterns 
on the ellipticine framework. This has led to the recent discoveries of substituted ellipticine and 
isoellipticines as new investigational probes with diverse pharmacology and exceptional in vivo 
activity (5 and 6, Figure 2) [17–20]. 
The 11-position of ellipticine has received little attention from medicinal chemists despite 
evidence that it may be a key position in order to affect the bioactivity and crucially selectivity of 
pharmacology [21]. The activity of the closely related olivicine series of compounds signifies that 
removal of the methyl group does little to affect the potency of the template especially in regard to 
topoisomerase activity and DNA intercalation (7, R = CH3, Figure 2) [22,23]. An olivacine derivative, 
S16020 (7, R = carboxamide) has also progressed to phase I clinical trials before being discontinued 
[24]. Despite synthesis of 11-formyl ellipticine 8 (Figure 2) almost 30 years ago, no concerted effort to 
functionalise this position is recorded in literature other than a carboxamide and a methyl ketone 
(only four reported compounds in total with carbonyl at 11-position).  
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The mechanisms by which ellipticine exerts its anticancer activity are particularly diverse.
These include topoisomerase II inhibition with associated DNA intercalation, well established in the
literature and clinically relevant [8–10]. Cytotoxic ellipticine metabolites via biooxidation at a number
of positions on the etracycle and subsequent adduct formation have also been iden fied as responsible
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for some of the effects [11]. Recently, ellipticines have been described to interact with kinases such as
c-Kit, AKT and CK2, and to influence the p53 tumour suppressor, all of which have key roles in cell
growth and progression [12–14]. Ellipticines have also been discovered to disrupt RNA polymerase I
transcription and stabilize pharmaceutically relevant G-quadruplexes and so there is significant and
continued interest in the biological effects of this compound class [15,16].
It is therefore evident that ellipticine and its derivatives exhibit multimodal activity with simple
substitutions on this template eliciting diverse effects. Despite their potency, there has been little
exploration of the functional space in this natural product outside of the 1-, 2-, 6- and 9-positions in
order to answer fundamental questions in pharmacology and effect on cells. A programme of research
has been initiated in this group in order to evaluate the effect of novel substitution patterns on the
ellipticine framework. This has led to the recent discoveries of substituted ellipticine and isoellipticines
as new investigational probes with diverse pharmacology and exceptional in vivo activity (5 and 6,
Figure 2) [17–20].
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i i s (5 and 6) with in vivo activity, Olivacine 7 and 11-formyle lipticine 8.
The 11-position of ellipticine has received little attention from medicinal chemists despite
evidence that it may be a key position in order to affect the bioactivity and crucially selectivity of
pharmacology [21]. The activity of the closely related olivicine series of compounds signifies that
removal of the methyl group does little to affect the potency of the template especially in regard to
topoisomerase activity and DNA intercalation (7, R = CH3, Figure 2) [22,23]. An olivacine derivative,
S16020 (7, R = carboxamide) has also progressed to phase I clinical trials before being discontinued [24].
Despite synthesis of 11-formyl ellipticine 8 (Figure 2) almost 30 years ago, o concerted effort to
functionalise this position is recorded in literature other than a carboxamide and a methyl ketone (only
four reported compounds in total with carbonyl at 11-position).
Molecular modelling of ellipticine in the active site of biological targets has postulated that
11-substitution with bulky or mobile functional groups would inhibit the intercalation process and
may reduce a number of undesirable effects associated with treatment [25]. This position has also been
implicated in the process of DNA adduct formation via oxidation [11].
To this end, we set out to functionalise the parent heterocycle and to exploit its known anticancer
activity: it has obvious potency across numerous spheres of biology and affects cells from development
to apoptosis [4]. Substitution of 11-position is an important step towards full SAR profiling of the
cellular effects of ellipticine derivatives. We document here the initial scoping of this chemical space
and probe of the anticancer activity through known ellipticine mechanisms.
2. Results and Discussion
2.1. Synthesis of 11-Substituted Ellipticine Derivatives
Since its isolation in 1959, the total synthesis of ellipticine has been accomplished many times and
most recent work in the area has focused on preparation of analogues and derivatives of ellipticine [3].
At the outset of this work there existed relatively few examples of 11-substituted ellipticines. Gribble et al.
had published a very versatile and efficient route in 1989, giving access to 5- and 11-substituted
Pharmaceuticals 2019, 12, 90 3 of 15
ellipticines [26–29]. This was further elaborated by Modi et al. to give 11-formylellipticine 8 and this
compound was chosen as the starting point for the current synthetic work [30,31].
2.1.1. Modification of 11-formylellipticine
11-Formylellipticine 8 was synthesised as previously described and initially the focus was to
provide a carboxylic acid handle for modification (Scheme 1) [30,31]. Hence, 8 was subjected to
oxidation under a number of conditions with the most successful conversion to carboxylic acid
9 achieved using sodium chlorite and dimethylsulfoxide (73% yield). Subsequent conversion to acid
chloride 10 allowed for introduction of amide functionality which was a key target in this series and
the benzylamine derivative 11 was prepared in two steps in 30% yield. The methyl ester 12 was also
prepared via similar methodology using carbonyldiimidazole.
Pharmaceuticals 2016, 9, x 3 of 5 
 
2. Results and Discussion 
2.1. Synthesis of 11-Substituted Ellipticine Derivatives 
Since its isolation in 1959, the total synthesis of ellipticine has been accomplished many times 
and most recent work in the area has focused on preparation of analogues and derivatives of 
ellipticine [3]. At the outset of this work there existed relatively few examples of 11-substituted 
ellipticines. Gribble et al. had published a very versatile and efficient route in 1989, giving access to 
5- and 11-substituted ellipticines [26–29]. This was further elaborated by Modi et al. to give 11-
formylellipticine 8 and this compound was chosen as the starting point for the curren  sy thetic work 
[30,31].  
. . . ifi ti  f -f r l lli ti i  
- l lli ti i    t i   i l  i   i iti ll  t  f   t  
i   c li  i  l  f r o ificati  (Sc e  1) [30,31]. ,   j t  t  
i ti    er of conditions with the most suc es ful conversion to carboxylic acid 9 
achieved using sodium chlorite and dimethylsulfoxide (73  iel ). Subsequent i  t  i  
l i   ll  f  i t ti  f i  f ti lit  i     t t i  t i  i   
t  l i  i ti     i  t  t  i   i l .  t l t    l  
 i  i il r t l  si  car yl ii i azole. 
 
Scheme 1. Formation of 11-substituted ellipticine amide 11 and ester 12. 
Interestingly, while attempting to form the acid initially with other oxidants the expected 
product was not isolated. On treatment of 8 with potassium permanganate under standard conditions 
the reaction resulted in base condensation of acetone and isolation of the novel α,β-unsaturated 
ketone 13 in 87% yield (Scheme 2).  
 
Scheme 2. α,β-Unsaturated ketone condensation product 13 from acetone solvent. 
c e e 1. For atio of 11-s bstit te elli tici e a i e 11 a ester 12.
Interestingly, while attempting to form the acid initially with other oxidants the expected product
was not isolated. On treatment of 8 with potassium permanganate under standard conditions the
reaction resulted in base condensation of acetone and isolation of the novel α,β-unsaturated ketone 13
in 87% yield (Scheme 2).
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Attempts at cyclisation of compound 13 using aluminium chloride in dichloromethane or
chloroform to form a new ring system were unsuccessful and unreacted starting material was
recovered. However, a Leuckart reaction gave the formamide 14 in 19% yield, the low yield owing to
difficulties in purification. However, the unsaturated ketone 13 provides an interesting template for
potential covalent adduct formation and will be revisited in the future.
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2.1.2. Modification of the 9-position of 11-substituted Ellipticines
Given the extensive literature background in 9-substituted ellipticines and the recent developments
in this area we next turned our focus to functionalization of this position. Initially, carboxylic acid 9
was derivatised via a Duff reaction to give the aldehyde 15 in 82% yield (Scheme 3) [32].
Pharmaceuticals 2016, 9, x 4 of 5 
 
Attempts at cyclisation of compound 13 using aluminium chloride in dichloromethane or 
chloroform to form a new ring system were unsuccessful and unreacted starting material was 
recovered. However, a Leuckart reaction gave the formamide 14 in 19% yield, the low yield owing to 
difficulties in purification. However, the unsaturated ketone 13 provides an interesting template for 
potential covalent adduct formation and will be revisited in the future.  
2.1.2. Modification of the 9-position of 11-substituted Ellipticines 
Given the extensive literature background in 9-substituted ellipticines and the recent 
developments in this area we next turned our focus to functionalization of this position. Initially, 
carboxylic acid 9 was derivatised via a Duff reaction to give the aldehyde 15 in 82% yield (Scheme 3) 
[32].  
Subsequent reaction of 15 with nucleophiles opens up opportunities for potential synthesis at 
either the 9- or the 11-position (Scheme 3). To probe the 11-position further, acid chloride formation 
prior to the addition of benzylamine (as seen in Scheme 1) was undertaken with the aim of generating 
amide 18. In this reaction, the product isolated was the imine 16 (83% yield) which was identified 
after full characterization. Confirmation of structure was given by subsequent treatment with 
aqueous acid which hydrolysed the product to starting material 15.  
Additional conformation of the imine 16 was provided by reduction of the imine with sodium 
cyanoborohydride in ethanol to give the novel amine 17.  
Scheme 3. Synthesis of 9- and 11-substituted ellipticines. 
2.1.3. 1H NMR Analysis of 11-Substituted Ellipticines 
A summary of the 1H NMR analysis is provided in Supplementary Materials (Figures S1–S3). Of 
note is the influence of conversion from aldehyde to carboxylic acid at the 11-position with 
corresponding upfield shift of C1 and C10 protons (reversed on formylation of the 9-position). The 
shift of the C10 proton is again evident on conversion of carboxylic acid to amide and ester. 
2.2. Biological Evaluation of 11-Substituted Ellipticines 
Given the interest in new ellipticines, several of the novel 9- and 11-substitued ellipticines were 
evaluated for their biological activity in cellular screens and by gel electrophoresis. In the first 
instance, inhibition of topoisomerase II (a well-known target of ellipticines) was assessed.  
2.2.1. Inhibition of Topoisomerase II  
Topoisomerase II inhibition is a clinically used cancer treatment and is considered to be a key 
mechanism of action for ellipticines [9]. Topoisomerase II has key functions in the change of 
topological structure of DNA and hence cell replication which can be evaluated using a decatenation 
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Subsequent reaction of 15 with nucleophiles opens up opportunities for potential synthesis at
either the 9- or the 11-position (Scheme 3). To probe the 11-position further, acid chloride formation
prior to the addition of benzylamine (as seen in Scheme 1) was undertaken with the aim of generating
amide 18. In this reaction, the product isolated was the imine 16 (83% yield) which was identified after
full characterization. Confirmation of structure was given by subsequent treatment with aqueous acid
which hydrolysed the product to starting material 15.
Additional conformation of the imine 16 was provided by reduction of the imine with sodium
cyanoborohydride in ethanol to give the novel amine 17.
2.1.3. 1H NMR Analysis of 11-Substituted Ellipticines
A summary of the 1H NMR analysis is provided in Supplementary Materials (Figures S1–S3).
Of note is the influence of conversion from aldehyde to carboxylic acid at the 11-position with
corresponding upfield shift of C1 and C10 protons (reversed on formylation of the 9-position). The shift
of the C10 proton is again evident on conversion of carboxylic acid to amide and ester.
2.2. Biological Evaluation of 11-Substituted Ellipticines
Given the interest in new ellipticines, several of the novel 9- and 11-substitued ellipticines were
evaluated for their biological activity in cellular screens and by gel electrophoresis. In the first instance,
inhibition of topoisomerase II (a well-known target of ellipticines) was assessed.
2.2.1. Inhibition of Topoisomerase II
Topoisomerase II inhibition is a clinically used cancer treatment and is considered to be a key
mechanism of action for ellipticines [9]. Topoisomerase II has key functions in the change of topological
structure of DNA and hence cell replication which can be evaluated using a decatenation assay.
As expected, the planar ellipticine 1 and the simple 9-substituted ellipticines (2,4,19) all displayed
excellent inhibition of topoisomerase II at 100 µM (Figure 3). On assessment of the 11-substituted
ellipticines, the majority were inactive against topoisomerase II but compounds 13 and 16 showed the
most promise. α,β-Unsaturated ketone 13 and 9-substituted imine 16 both represent new templates for
discovery. Both compounds were evaluated in a subsequent three-fold dilution assay (at 100, 10 and
1µM) where it became apparent that activity reduced significantly below the initial test concentration.
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Notwithstanding this, the emergence of two diverse templates for topoisomerase inhibition will be of
keen interest to the field and future efforts will aim to increase the potency of this interaction.
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Figure 3. Screen of topoiso erase i i it r activity of th ellipticine derivatives at 100 µM.
A = Positive Control (kDNA + ATP + Topo II); B = Negative Control (kDNA + ATP + Topo II + 100 µM
Ellipticine); sequent lanes all screened at 100 µM: 1 = Ellipticine 1; 2 = 9-Meth xyellipticine 2;
3 = 9-Formylellipticine 19; 4 = 9-Hydroxyellipticine 4; 5 = 8; 6 = 9; 7 = 3; 8 = 15; 9 = 16; 10 = 17; 11 = 11.
2.2.2. Inhibition of Cancer Cell Growth
Having identified some limited topoisomerase activity, screening of the 11-substituted ellipticine
test set was next conducted by assessment of inhibition of cancer cell growth. Initial evaluation of
anticancer activity at the National Cancer Institute focuses on the effect of each individual compound on
the growth of up to 60 cancer cell lines at a specific concentration (10 µM). The results are summarised
in Table 1 (see Supplementary Material for full data, Figures S5–S10).
Table 1. 11-Substituted ellipticine topoisomerase activity and National Cancer Institute (NCI) mean
growth percent (single dose).
R1
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 R1R2 Topo II 
Inhibitiona  
NSC No NCI Mean 
Growth % 
8 CHO H –  Not tested 
9 COOH H – 762124 99.92 
11 CONHCH2Ph H – 762144 21.22 
13 CH=CH-C(O)Me H + 762123 17.83 
15 COOH CHO – 762141 95.56 
R2
Topo II
Inhibition a NSC No
NCI Mean
Growth %
8 CHO H − Not tested
9 COOH H − 762124 99.92
11 CONHCH2Ph H − 762144 21.22
13 CH=CH-C(O)Me H + 762123 17.83
15 COOH CHO − 76 141 95.56
16 COO− +NH3CH2Ph CH=NCH2Ph + 762142 106.19
17 COOH CH2NHCH2Ph − 762143 101.72
a R1 = C-9 substituent; R2 = C11 substituent (+) Inhibition observed at 100 µM; (−) no activity observed at 100 µM.
Inhibition of Cancer Cell Growth—One Dose Assay
National Cancer Institute (N I) evaluation of 11-substituted ellipticines identifies significant
effects on the growth of the - ell line panel with mean growth values ranging from 18% to 106%.
The Mean Growth perc nt is a ref rence tool whereby screening at 10 µM concentration is used to
filter active anticancer compounds. Of the six compounds tested, two (11-substituted amide 11 and
conj gated keto 13) achieved Mean Growth percent ges of <25% and fulfilled the requirements for
progressi n to the five dose assay (Table 1). Of the other four compounds growth percentages were
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between 96% and 106% and hence have no effect on the growth as an average across the 60 cell lines.
Compounds 9, 15, 16 and 17 elicited very similar effects being most active against renal cancer cell line
UO-31 (range 63%–76% growth) and breast cancer cell lines MCF7 and MDA-MB-231/ATCC (range
68%–87% growth) but have little effect on the other cell lines of the screen (Figures S5, S8–S10).
In contrast, benzylamide 11 and ketone 13 had significant anticancer effects with differing cellular
profiles. Ketone 13 is associated with a non-specific pattern with the range of cell growths (lowest
to highest) of 77% whereas benzylamide 11 has a range of 165% and there is an evident difference in
cell line effects. At 10 µM, compound 11 is cytotoxic (negative growth percentage) to 15 of the 60 cell
lines whereas compound 13 to only four cell lines. It is noticeable that a large number of cell lines are
refractory to benzylamide 11 which suggests there may be a targeted effect. It is also obvious from
this preliminary screen that there is chemical space at the 11-position of ellipticine to accommodate
anticancer activity.
Inhibition of Cancer Cell Growth—Five Dose Assay
The progression to evaluation at five dose assay confirmed the potency of both 11-substituted
ellipticines 11 and 13 and their specific effects on cells seen in the one dose screen. Benzylamide 11
exerts a broad range of activity from cytostatic to cytotoxic at dose ranges from 1 to 100 µM (Table 2;
Figure S11). In specific, the activity of this compound against HOP62, SNB75, OVCAR-3, OVCAR-4
and 786-0 is exceptional with more than 50% cytotoxicity measured after 48 h incubation (at 10 µM).
Growth is restricted across the other cell lines but there is clear selective cytotoxicity. In addition
it can be seen (Figure S12) that a number of cell lines are refractory with no evident effect on cell
growth of cancer subtypes, in particular melanoma: Leukaemia (HL-60), Lung (EKVX), CNS (SF-295,
SNB-19), Melanoma (MALME-3M, M14, SK-MEL-2, SK MEL-28, UACC-257), Ovarian (OVCAR-5,
NCI/ADR-RES) and Breast (T-47D).





GI50 LC50 GI50 LC50
HOP-62 Lung 2.15 >100 1.77 26.0
SW-620 Colon 2.86 >100 1.65 44.0
SNB-75 CNS 2.05 >100 2.65 34.8
OVCAR-3 Ovarian 2.33 <10 2.53 28.0
OVCAR-4 Ovarian 1.71 6.19 2.88 41.5
786-0 Renal 2.79 72.0 2.79 29.8
A498 Renal 50.5 >100 0.386 7.48
UO-31 Renal 2.73 >100 1.25 33.8
MCF7 Breast 2.71 >100 1.74 52.3
MDA-MB-231/ATCC Breast 2.43 >100 1.74 41.3
HS578T Breast 2.61 >100 1.96 48.4
1 data reported in µM values from NCI 60 cell line five dose assay; GI50: Growth Inhibition 50%; LC50: Lethal
concentration 50%.
Ketone 13 exerts a far more cytotoxic effect across all cell lines with consistent cell death evident
at 10 µM as in the one dose screen (Table 2, LC50 column; Figures S13 and S14). Aside the exception of
the leukaemia cell panel, all cells are killed by 100 µM of 13 which suggests a potent and common
mechanism of action. The compound is exceptionally potent against the growth of A498 renal cancer
cells with a GI50 of 386 nM and merits future investigation. In the design of compound 13, the
Michael acceptor moiety is presumably involved in alkylation of the essential machinery of the cell
and development of this is the subject of current work.
In comparing the global effect of both 11 and 13 (Figures S13 and S16) it is evident that they affect
cell growth by different mechanisms as would be expected from their structures. In specific, compound
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11 has the potential for use in ovarian cancers given its exceptional toxicity against the OVCAR-3 and
OVCAR-4 phenotypes (LC50 6.2 and <10 µM respectively; OVCAR-4 value assigned due to inflection
of graph). OVCAR-3 and OVCAR-4 are both mutant p53 status but have individual profiles with
OVCAR-3 having known upregulation of BRCA2-interacting transcriptional repressor and cyclin E1.
OVCAR-4 in turn has been identified as a good model cell line for High Grade Serious Ovarian Cancer
(HGSOC) which make these findings significant from a clinical perspective [33].
2.3. COMPARE Analysis of Compounds 11 and 13
COMPARE analysis was performed on the NCI COMPARE algorithm in order to identify
correlations with known anticancer agents within the NCI database. Both compound 11 and 13 were
analysed and with a specific focus on two subsets of the database: synthetic compounds and mechanistic
set. Compound 13 gave a number of correlations as high as 0.74 with the most relevant mechanistic hit
being to Chrysanthemic acid (NSC 11779) but this must be seen in the overall non-specific profile of
activity of 13 and its limited potency.
However, on analysis of 11 in the synthetic compounds set, the top ranked correlation (0.6) is
to SCH1473759 (NSC 761691) which has recently been reported as a picomolar inhibitor of Aurora
kinases [34]. Again, while an important finding and a good match of cellular activity profile, this result
must be seen in the context of potency with SCH1473759 having >100 the potency of 11 in the NCI assay
(Figure S17). Compound 11 also gave rise to a correlation of 0.58 to Aclarubicin (Aclacinomycin A,
NSC 208734) being the top hit of the mechanistic compound set. Aclarubicin has known topoisomerase
inhibitory and recently reported histone eviction from open chromatin activity so despite the lack of
evident topoisomerase activity of 11, this result merits further evaluation in respect of its interaction
with DNA and DNA interacting enzymes [35].
3. Materials and Methods
Solvents were distilled prior to use as follows: dichloromethane was distilled from phosphorous
pentoxide; ethyl acetate was distilled from potassium carbonate; ethanol and methanol were distilled
from magnesium in the presence of iodine; toluene was distilled from sodium and benzophenone;
hexane was distilled prior to use; tetrahydrofuran was freshly distilled from sodium and benzophenone.
Diethyl ether was obtained pure from Riedel-de Haën. Organic phases were dried using anhydrous
magnesium sulphate. All commercial reagents were used without further purification unless otherwise
stated. All samples were confirmed as >95% pure by use of high resolution LCMS analysis.
Infrared spectra were recorded as a thin film on sodium chloride plates for liquids or potassium
bromide (KBr) disc for solids on a Perkin Elmer Spectrum 100 FT-IR spectrometer.
1H (300 MHz) and 13C (75 MHz) NMR spectra were recorded on a Bruker Avance 300 NMR
spectrometer. 1H (600 MHz) and 13C (150.9 MHz) NMR spectra were recorded on a Bruker Avance III
600 MHz NMR spectrometer equipped with a dual CH cryoprobe. All spectra were recorded at room
temperature (~20 ◦C) in deuterated dimethylsulfoxide (DMSO-d6) were assigned using the DMSO-d6
peak as the reference peak. Chemical shifts (δH and δC) are expressed in parts per million (ppm)
relative to the reference peak. Coupling constants (J) are expressed in Hertz (Hz). Splitting patterns in
1H NMR spectra are designated as s (singlet), br s (broad singlet), d (doublet), br d (broad doublet),
t (triplet), q (quartet), dd (doublet of doublets), dt (doublet of triplets), ddd (doublet of doublet of
doublets), ddt (doublet of doublet of triplets) and m (multiplet).
Low resolution mass spectra were recorded on a Waters Quattro Micro triple quadrupole
spectrometer (QAA1202) in electrospray ionisation (ESI) mode using 50% acetonitrile:water containing
0.1% formic acid as eluent. High resolution mass spectra (HRMS) were recorded on a Waters LCT Premier
Time of Flight spectrometer (KD-160) in electrospray ionisation (ESI) mode using 50% acetonitrile:ater
containing 0.1% formic acid as eluent.
Melting points were measured in a uni-melt Thomas Hoover capillary melting point apparatus
and are uncorrected. Thin layer chromatography (TLC) was carried out on precoated silica gel plates
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(Merck 60 PF254) or aluminium oxide TLC paltes (Sigma). Visualisation was achieved by UV light
detection (254 nm).
5-Methyl-6H-pyrido[4,3-b]carbazole-11-carboxylic acid 9. 5-Methyl-6H-pyrido[4,3-b]carbazole
-11-carbaldehyde 8 (92 mg, 0.353 mmol) in acetonitrile (9 mL) was treated with dimethylsulfoxide
(0.03 mL, 0.423 mmol) and conc. sulfuric acid (0.3 mL, 0.622 mmol). A solution of sodium chlorite
(48 mg, 0.530 mmol) in water (3 mL) was added dropwise and the reaction mixture was stirred at room
temperature overnight. The reaction was quenched with sodium sulfite (22 mg, 0.177 mmol) in water
(1 mL). The acetonitrile was evaporated to leave an aqueous solution, which was carefully adjusted to
pH 5 with saturated aqueous sodium bicarbonate to precipitate the product. The mixture was cooled to
0 ◦C, filtered and washed with water (3 mL), to give 5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylic
acid 9. The orange solid was dried at 0.02 mbar for 24 h (71 mg, 73.2%). m.p. >300 ◦C; vmax/cm−1
(KBr): 3161 (NH), 3010 (OH broad), 1689 (C=O), 1648 (C=C arom.), 1597 (C=C arom.), 1488, 1463,
1417, 1241 (C-O stretch), 1109; δH (300 MHz, DMSO-d6): 2.88 [3H, s, C(5)CH3], 7.26 [1H, t, J = 7.9,
C(9)H], 7.55–7.62 [2H, m, C(7)H, C(8)H], 8.03 [1H, d, J = 5.9, C(3)H], 8.21 [1H, d, J = 7.8, C(10)H], 8.47
[1H, d, J = 5.9, C(4)H], 9.43 [1H, s, C(1)H], 11.64 [1H, s, N(6)H]; δC (75.5 MHz, DMSO-d6): 12.3 [3H, s,
C(5)CH3], 111.5 [CH, C(7)H], 113.3 (C, aromatic C), 117.7 [CH, C(3)H], 118.5 (C, aromatic C), 120.0 [CH,
C(9)H], 120.3 (C, aromatic C), 122.3 (C, aromatic C), 123.1 [CH, C(10)H], 124.9 (C, aromatic C), 129.1
[CH, C(8)H], 132.2 (C, aromatic C), 136.1 [CH, C(4)H], 141.9 (C, aromatic C), 143.1 (C, aromatic C),
147.9 [CH, C(1)H], 168.8 [C, C(11)COOH]; m/z (ESI+): 277 [(M+H)+ 40%], 115 (100%); HRMS (ESI+):
Exact mass calculated for [C17H13N2O2]+ 277.0977. Found 277.0977.
5-Methyl-6H-pyrido[4,3-b]carbazole-11-carbonylchloride 10. 5-Methyl-6H-pyrido[4,3-b]carbazole
-11-carboxylic acid 9 (99 mg, 0.358 mmol) in dichloromethane (50 mL), under N2, was treated with
oxalyl chloride (0.04 mL, 0.459 mmol). Slight fizzing was observed on addition and mixture was stirred
at room temperature for 20 h. The bright orange suspension was evaporated under reduced pressure.
IR analysis showed the carbonyl peak at 1785 cm−1 indicating acid chloride formation.
N-Benzyl-5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxamide 11. 5-Methyl-6H-pyrido[4,3-b]
carbazole-11-carboxylic acid 9 (99 mg, 0.358 mmol) in dichloromethane (50 mL), under N2, was treated
with oxalyl chloride (0.04 mL, 0.459 mmol) and stirred at room temperature for 20 h. The mixture was
evaporated under reduced pressure, cooled to 0 ◦C under N2, and treated drop-wise with benzylamine
(2 mL, 18.3 mmol). After stirring for 1 h, diethyl ether (40 mL) was added, the mixture was cooled
and filtered to give a cream solid (220 mg) containing the desired product and residual benzylamine.
This was stirred with diethyl ether and decanted (3 × 40 mL). Purification by column chromatography,
eluting with dichloromethane:methanol (100:0–95:5), gave product 11 as a yellow solid (39 mg, 30%).
m.p. 294–296 ◦C; vmax/cm−1 (KBr): 3159 (NH), 3051 (CH) 1731 (C=O), 1621 (C=C arom.), 1600 (C=C
arom.), 1542, 1466, 1410, 1245; δH (600 MHz, DMSO-d6): 2.79 [3H, s, C(5)CH3], 4.65–4.70 [2H, m,
CONHCH2], 6.98 [1H, t, J = 7.4, C(9)H], 7.28 [1H, t, J = 7.2, N-benzyl-C(4)H], 7.36 [2H, t, J = 7.3,
N-benzyl-C(2)H, C(6)H], 7.43–7.50 [4H, m, C(7)H, C(8)H, N-benzyl-C(3)H, C(5)H], 7.72 [1H, d, J = 7.8,
C(10)H], 7.93 [1H, d, J = 5.9, C(3)H], 8.37 [1H, d, J = 5.1, C(4)H], 9.19 [1H, s, C(1)H], 9.41 [1H, t,
J = 5.9, C(11)CONH], 11.46 [1H, s, N(6)H]; δC (150.9 MHz, DMSO-d6): 12.2 [CH3, C(5)CH3], 43.1
[CH2, C(11)CONHCH2], 110.9 (CH, aromatic CH), 111.3 (C, aromatic C), 116.0 [CH, C(3)H], 119.1 [CH,
C(9)H], 119.8 (C, aromatic C), 120.9 (C, aromatic C), 121.1 (C, aromatic C), 122.8 [CH, C(10)H], 127.1
[CH, N-benzyl-C(4)H], 127.2 (C, aromatic C), 127.9 (CH, aromatic CH), 128.0 (CH, aromatic CH), 128.2
(CH, aromatic CH), 128.4 (CH, aromatic CH), 128.5 (CH, aromatic CH), 131.7 (C, aromatic C), 138.9
(C, aromatic C), 140.4 (C, aromatic C), 140.7 [CH, C(4)H], 142.7 (C, aromatic C), 150.1 [CH, C(1)H],
167.1 [C, C(11)CONH]; m/z (ESI+): 366 [(M+H+), 100%]; HRMS (ESI+): Exact mass calculated for
[C24H20N3O]+ 366.1606. Found 366.1615.
Methyl 5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylate 12. 5-Methyl-6H-pyrido[4,3-b]carbazole
-11-carboxylic acid 9 (99 mg, 0.358 mmol) in dimethylformamide (8 mL) under N2, was heated gently
until the acid dissolved. Carbonyldiimidazole (70 mg, 0.430 mmol) was added and the solution was
heated at 120 ◦C for 4 h. The mixture was cooled to 0 ◦C and diethyl ether (20 mL) was added. The
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resulting precipitate was filtered and washed (diethyl ether 10 mL). The solid was cooled to 0 ◦C
and treated dropwise with methanol (10 mL). The mixture was stirred at r.t. for 1 h and heated to
reflux for 5 h. On cooling, a precipitate formed which was filtered to give the methyl ester, methyl
5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylate 12 (14 mg, 14%). m.p. 247–250 ◦C; vmax/cm−1
(KBr): 3147 (NH), 3008 (CH), 1742 (C=O), 1634 (C=C arom.), 1589 (C=C arom.), 1457, 1422, 1246 (C-O
stretch), 1095; δH (300 MHz, DMSO-d6): 2.89 [3H, s, C(5)CH3], 4.22 [3H, s, C(11)COOCH3], 7.27 [1H,
overlapping ddd, J = 8.0, 5.8, 2.3, C(9)H], 7.57–7.63 [2H, m, C(7)H, C(8)H], 7.99 [1H, d, J = 8.0, C(10)H],
8.04 [1H, d, J = 6.1, C(3)H], 8.50 [1H, br s, C(4)H], 9.38 [1H, br s, C(1)H], 11.73 [1H, s, N(6)H]; δC
(150.9 MHz, DMSO-d6): 12.4 [CH3, C(5)CH3], 53.1 [CH3, C(11)COOCH3], 111.3 [CH, C(7)H or C(8)H],
113.7 (C, aromatic C), 116.2 [CH, C(3)H], 119.6 [CH, C(9)H], 120.2 (C, aromatic C), 121.3 (C, aromatic C),
121.8 (C, aromatic C), 122.5 [CH, C(10)H], 128.7 [CH, C(7)H or C(8)H], 131.6 (C, aromatic C), 140.2 (C,
aromatic C), 140.9 [CH, C(4)H], 143.1 (C, aromatic C), 149.8 [CH, C(1)H], 168.4 [C, C(11)C=O]; m/z
(ESI+): 291 [(M+H)+, 100%]. HRMS (ESI+): Exact mass calculated for [C18H15N2O2]+ 291.1134. Found
291.1121.
(E)-4-(5-methyl-6H-pyrido[4,3-b]carbazol-11-yl)but-3-en-2-one 13. A stirred solution of 5-methyl
-6H-pyrido[4,3-b]carbazole-11-carbaldehyde 8 (300 mg, 1.15 mmol) in acetone (70 mL) was treated
drop-wise with potassium permanganate (364 mg, 2.30 mmol) in water (70 mL). The mixture was
stirred at r.t. for 1 h and heated to reflux for 22 h. Sodium bicarbonate (244 mg, 2.30 mmol) was added
and stirred for 20 min. The mixture was filtered through celite and washed with water (100 mL) and
acetone (200 mL). The filtrate was concentrated under reduced pressure to remove the acetone and then
acidified to pH 5 with 20% aqueous HCl. The aqueous layer was extracted with chloroform:methanol
(90:10, 3 × 100 mL). Organic extracts were combined and washed with water (1 × 100 mL) and
brine (1 × 100 mL), dried over magnesium sulphate and evaporated under reduced pressure to give
an orange solid (300 mg). Analysis showed that the desired carboxylic acid 9 had not formed but
instead the condensation product (E)-4-(5-methyl-6H-pyrido[4,3-b]carbazol-11-yl)but-3-en-2-one 13
(87.0%). m.p. 263–265 ◦C; vmax/cm−1 (KBr): 3149(NH), 3087 (CH), 2982 (asymm. CH3 stretch), 2883
(symm. CH3 stretch), 1664 (C=O), 1620 (C=C), 1592 (C=C arom.), 1464, 1404, 1383, 1243; δH (300 MHz,
DMSO-d6): 2.61 [3H, s, COCH3], 2.84 [3H, s, C(5)CH3], 6.75 [1H, d, J = 16.6, C(11)CH=CH], 7.25 [1H,
overlapping ddd, J = 8.0, 6.6, 1.5, C(9)H], 7.53–7.61 [2H, m, C(7)H, C(8)H], 7.98 [1H, dd, J = 6.1, 0.7,
C(3)H], 8.14 [1H, d, J = 8.0, C(10)H], 8.47 [1H, d, J = 6.1, C(4)H], 8.59 [1H, d, J = 16.6, C(11)CH=CH],
9.58 [1H, s, C(1)H], 11.57 [1H, s, N(6)H]; δC (75.5 MHz, DMSO-d6): 12.2 [CH3, C(5)CH3], 27.8 (CH3,
COCH3), 111.1 [CH, C(7)H], 111.7 (C, aromatic C), 115.9 [CH, C(3)H], 119.4 [CH, C(9)H], 120.5 (C,
aromatic C), 121.9 (C, aromatic C), 122.4 (C, aromatic C), 123.6 [CH, C(10)H], 126.0 (C, aromatic C),
127.9 [CH, C(8)H], 132.3 (C, aromatic C), 135.9 [CH, C(11)CH=CH], 138.4 [CH, C(11)CH=CH], 140.2 (C,
aromatic C), 140.9 [CH, C(4)H], 143.0 (C, aromatic C), 150.1 [CH, C(1)H], 197.8 (C, C=O); m/z (ESI+):
301[(M+H)+ 100%]; HRMS (ESI+): Exact mass calculated for [C20H17N2O]+ 301.1341. Found 301.1348.
(E)-N-(4-(5-methyl-6H-pyrido[4,3-b]carbazol-11-yl)but-3-en-2-yl)formamide 14. (E)-4-(5-Methyl
-6H-pyrido[4,3-b]carbazol-11-yl)but-3-en-2-one 13 (91 mg, 0.303 mmol), formamide (0.2 mL, 5.03 mmol)
and formic acid (0.1 mL, 2.65 mmol) were heated to 150 ◦C for 1.5 h, at which point TLC analysis
indicated consumption of the starting material. On cooling, saturated aqueous sodium bicarbonate
(8 mL) was added and extraction was attempted with dichloromethane:methanol (90:10), however the
organic extracts contained no material. The aqueous layer was treated with 20% aqueous HCl to pH
1, stirred for 20 min and then adjusted to pH 10 with 20% aqueous NaOH. The aqueous layer was
extracted with dichloromethane–methanol (90:10 3 × 30 mL and 80:20 4 × 30 mL), dried and evaporated
under reduced pressure to give an orange solid (64 mg). Purification by column chromatography on
alumina, eluting with dichloromethane:methanol (97:3–90:10) gave three fractions. The largest of these
(34 mg) was repurified by chromatography on silica to give an orange solid (19 mg). This was found to
be the formamide, (E)-N-(4-(5-methyl-6H-pyrido[4,3-b]carbazol-11-yl)but-3-en-2-yl)formamide 14. δH
(300 MHz, DMSO-d6): 1.47 [3H, d, J = 6.9, C(11)CH=CH–CH(CH3)], 2.83 [3H, s, C(5)CH3], 4.88–4.95
[1H, m, C(11)CH=CH–CH(CH3)], 6.14 [1H, dd, J = 16.2, 5.6, C(11)CH=CH], 7.21 [1H, overlapping ddd,
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J = 8.0, 6.7, 1.4, C(9)H], 7.36 [1H, d, J = 16.5, C(11)CH=CH], 7.52 [1H, td, J = 7.4, 1.1, C(8)H], 7.56–7.59
[1H, m, C(7)H], 7.99 [1H, br s, NHCHO], 8.23 [1H, br s, C(3)H], 8.33 [1H, d, J = 7.7, C(10)H], 8.43 [1H,
br s, NHCHO], 8.54 [1H, d, J = 7.5, C(4)H], 9.58 [1H, br s, C(1)H], 11.51 [1H, s, N(6)H]; m/z (ESI+): 330
[(M+H)+ 60%], 169 (100%); HRMS (ESI): Exact mass calculated for [C21H20N3O]+ 330.1606. Found
330.1619.
9-Formyl-5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylic acid 15. 5-Methyl-6H-pyrido[4,3-b]
carbazole-11-carboxylic acid 9 (497 mg, 1.80 mmol) in trifluoroacetic acid (60 mL), was treated with
hexamethylenetetramine (2.522 g, 18.0 mmol) portionwise over 5 min and heated to reflux for 25 min.
On cooling, the reaction mixture was concentrated to approx. one quarter volume, water (30 mL) was
added and the solution was transferred to a large conical flask (500 mL). The solution was cooled to
0 ◦C and neutralized with solid sodium bicarbonate while stirring vigorously. The mixture was stirred
at 0 ◦C for 1 h, readjusted to pH 7 and filtered to give a brown solid which was dried at 0.02 mbar for
2 days (449 mg, 81.9%). m.p. 315–317 ◦C; vmax/cm−1 (KBr): 3069 (OH broad), 1677 (C=O × 2, broad),
1583 (C=C arom.), 1472, 1404, 1349, 1242 (C-O stretch), 1128, 808; δH (600 MHz, DMSO-d6): 2.88 [3H,
s, C(5)CH3], 7.72 [1H, d, J = 8.3, C(7)H], 8.04 [1H, d, J = 6.0, C(3)H], 8.10 [1H, d, J = 8.4, C(8)H], 8.50
[1H, d, J = 6.0, C(4)H], 8.80 [1H, s, C(10)H], 9.51 [1H, s, C(1)H], 10.04 [1H, s, C(9)CHO], 12.14 [1H,
s, N(6)H]; δC (150.9 MHz, DMSO-d6): 12.3 [3H, s, C(5)CH3], 111.4 [CH, C(7)H], 113.0 (C, aromatic
C), 116.2 [CH, C(3)H], 119.7 (C, aromatic C), 120.4 (C, aromatic C), 121.3 (C, aromatic C), 125.7 [CH,
C(10)H], 128.5 (C, aromatic C), 129.8 [CH, C(8)H], 129.9 (C, aromatic C), 132.4 (C, aromatic C), 140.8
[CH, C(4)H], 141.1 (C, aromatic C), 146.9 (C, aromatic C), 150.7 [CH, C(1)H], 169.2 [C, C(11)COOH],
191.6 [CH, C(9)CHO]; m/z (ESI+): 305 [(M+H)+ 70%], 155 (40%), 64 (100%); HRMS (ESI+): Exact mass
calculated for [C18H13N2O3]+ 305.0926. Found 305.0940.
Benzylammonium9-((benzylimino)methyl)-5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylate16.
A suspension of 9-formyl-5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylic acid 15 (194 mg,
0.638 mmol) in dichloromethane (65 mL), under N2, was treated with oxalyl chloride (0.08 mL,
0.917 mmol) and stirred at room temperature overnight. Additional oxalyl chloride (0.08 mL,
0.917 mmol), was added and the reaction was stirred for 4 h. The mixture was evaporated under
reduced pressure, cooled to 0 ◦C under N2, and treated drop-wise with benzylamine (2 mL,
18.3 mmol). After stirring for 1 h, diethyl ether (40 mL) was added, the mixture was cooled
and filtered to give a yellow solid. Crude analysis showed this to contain residual benzylamine.
Recrystallisation from dichloromethane followed by a second recrystallisation from methanol
gave product still containing benzylamine in 1:1 ratio with product. To investigate whether an
amide or imine had formed, the product (27 mg) was dissolved in dichloromethane:methanol
(90:10, 10 mL) and washed with 1M HCl (10 mL). The organic layer was dried and evaporated
under reduced pressure. NMR and MS analysis showed that the compound had hydrolysed to
the starting material 15, indicating imine rather than amide formation. Full analysis (along with
subsequent reduction of the imine) confirmed the product as the imine salt, benzylammonium
9-((benzylimino)methyl)-5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylate 16 (208 mg, 82.9%). m.p.
241–243 ◦C; vmax/cm−1 (KBr): 3029 (NH), 2864 (OH, broad), 1598 (C=O), 1572 (C=C arom.), 1494,
1450, 1402, 1347, 1278, 1244 (C-O stretch); δH (300 MHz, DMSO-d6): 2.81 [3H, s, C(5)CH3], 4.06 [2H,
s, benzylammmonium-CH2], 4.74 [2H, s, C(9)CH=NCH2], 7.23–7.29 [1H, m, iminobenzyl-C(4)H],
7.33–7.42 [7H, m, iminobenzyl-C(2)H, C(3)H, C(5)H, C(6)H, benzylammmonium-C(3)H, C(4)H, C(5)H],
7.48 [2H, dd, J = 7.7, 1.7, benzylammmonium-C(2)H, C(6)H], 7.56 [1H, d, J = 8.3, C(7)H], 7.91 [1H, dd,
J = 6.1, 0.7, C(3)H], 7.97 [1H, dd, J = 8.4, 1.6, C(8)H], 8.38 [1H, d, J = 6.1, C(4)H], 8.52 [1H, s, C(9)CH=N],
8.73 [1H, d, J = 1.1, C(10)H], 9.50 [1H, s, C(1)H], 11.64 [1H, s, N(6)H]; δC (75.5 MHz, DMSO-d6): 12.0
[CH3, C(5)CH3], 42.3 [CH2, benzylammonium CH2], 64.1 [CH2, C(9)CH=N–CH2], 110.6 (CH, aromatic
CH), 115.7 (CH, aromatic CH), 119.2 (C, aromatic C), 119.4 (C, aromatic C), 122.2 (C, aromatic C), 124.3
(CH, aromatic CH), 125.1 (C, aromatic C), 126.7 (CH, aromatic CH), 127.3 (C, aromatic C), 127.9 (CH,
2 × aromatic CH), 128.2 (CH, aromatic CH), 128.3 (CH, 2 × aromatic CH), 128.5 (CH, 2 × aromatic
CH), 128.6 (CH, aromatic CH), 128.7 (CH, 2 × aromatic CH), 131.3 (C, aromatic C), 132.1 (C, aromatic
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C), 134.6 (C, aromatic C), 139.9 (CH, aromatic CH), 140.5 (CH, aromatic CH), 141.1 (C, aromatic C),
144.3 (C, aromatic C), 144.5 (C, aromatic C), 152.0 (CH, aromatic CH), 162.2 (C, C=O); m/z (ESI+):
394 [(M+H)+ 20%], 305 (20%), 108 (100%); HRMS (ESI+): Exact mass calculated for [C25H20N3O2]+
394.1556. Found 394.1560.
9-((Benzylamino)methyl)-5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylic acid 17. A solution
of benzylammonium 9-((benzylimino) methyl)-5-methyl-6H-pyrido[4,3-b]carbazole-11-carboxylate 16
(88 mg, 0.224 mmol) in absolute ethanol (12 mL) was treated with sodium cyanoborohydride (21 mg,
0.338 mmol) and heated to reflux for 4.5 h. The solution was evaporated under reduced pressure and
water (10 mL) was added. The mixture was stirred for 15 min, cooled and filtered. The orange solid
was washed with water (5 mL) and diethyl ether (10 mL) and dried at 0.1 mbar for 24 h (56 mg, 62.9%).
m.p. >300 ◦C (without melting); vmax/cm−1 (KBr): 3370 (NH), 3188 (OH, broad), 3056 (CH), 1596
(C=O), 1565 (C=C arom.), 1482, 1403, 1348, 1247 (C-O stretch); δH (600 MHz, DMSO-d6): 2.73 [3H, s,
C(5)CH3], 3.89 [2H, s, one of CH2], 4.04 [2H, s, one of CH2], 7.21–7.26 [3H, m, N-benzyl-C(3)H, C(4)H,
C(5)H], 7.39–7.40 [2H, m, N-benzyl-C(2)H, C(6)H], 7.46 [1H, d, J = 7.3, C(7)H], 7.53 [1H, d, J = 7.5,
C(8)H], 7.82 [1H, d, J = 5.6, C(3)H], 8.29 [1H, d, J = 5.6, C(4)H], 8.42 [1H, s, C(10)H], 9.44 [1H, s, C(1)H],
11.39 [1H, s, N(6)H]; δC (150.9 MHz, DMSO-d6): 12.0 [CH3, C(5)CH3], 50.3 (CH2), 51.4 (CH2), 108.3
(C, aromatic C), 110.4 [CH, C(7)H], 115.6 [CH, C(3)H], 119.1 (C, aromatic C), 119.3 (C, aromatic C),
122.4 (C, aromatic C), 124.5 [CH, C(10)H], 127.7 [CH, N-benzyl-C(4)H], 128.1 (CH, C(8)H], 128.3 [CH,
N-benzyl-C(3)H, N-benzyl-C(5)H], 129.0 [CH, N-benzyl-C(2)H, N-benzyl-C(6)H], 129.1 (C, aromatic C),
132.0 (C, aromatic C), 133.7 (C, aromatic C), 136.0 (C, aromatic C), 140.2 [CH, C(4)H], 141.3 (C, aromatic
C), 142.2 (C, aromatic C), 152.2 [CH, C(1)H], 170.8 (C, C=O); m/z (ESI+): 396 [(M+H)+ 80%], 306 (100%);
HRMS (ESI+): Exact mass calculated for [C25H22N3O2]+ 396.1712. Found 396.1729.
Topoisomerase II decatenation assay. The decatenation assay kit was obtained from Inspiralis,
Norwich Bioincubator, Norwich Research Park, Colney, Norwich, UK. The kit comprised of the
following: assay buffer (supplied as 10× stock) containing 50 mM Tris.HCl (pH 7.5), 125 mM NaCl,
10 mM MgCl2, 5 mM DTT and 100 µg/mL albumin; dilution buffer containing 50 mM Tris. HCl (pH 7.5),
100 mM NaCl, 1 mM DTT, 0.5 mM EDTA, 50% (v/v) glycerol, 50 µg/mL albumin; ATP 30 mM; kDNA
(100 ng/µl); 10 U/µL human topoisomerase II in dilution buffer; 5× stop buffer containing 2.5% SDS,
15% Ficoll-400, 0.05% bromophenol blue, 0.05% xylene cyanol and 25 mM EDTA. Tris-acetate-EDTA
buffer (supplied as 10X buffer) and agarose were obtained from Sigma Life Sciences (Dublin, Ireland)
and Safe View Stain was supplied by NBS Biologicals, Cambridgeshire, England.
The topo II decatenation assay protocol involved initial incubation of each inhibitor candidate
(100 µM) along with a stock solution containing water, ATP, assay buffer, kDNA obtained from the
mitochondrial DNA of Crithidia fasciculate, and topo II, at 37 ◦C for 1 h. Following addition of stop
buffer, agarose DNA gel electrophoresis was run at 50 V for 2 h using a Consort EV243 power pack, to
determine the relative amounts of decatenated DNA bands obtained in each compound lane. Positive
(water), as well as negative controls (ellipticine) were incorporated in order to validate the results
of each run. The resulting gels were viewed under UV light using a DNR Bio-Imaging System and
photographed using GelCapture software.
NCI-60 Anti-cancer screening. Tested compounds were initially solubilised in DMSO, diluted
into RPMI 1640 and 5% fetal bovine serum/L-glutamine, and added to 96-well plates containing cell
lines previously cultured for 24 h. After 48-h incubation, the media were removed, and the cells were
fixed and stained with sulforhodamine B to determine overall percent growth/total protein content.
Unbound dye was removed with five washes of 1% acetic acid, and the plates were allowed to air dry.
The dye was then resolubilised in Tris buffer, and the colorimetric absorbance was measured (515 nm).
Growth inhibition was measured relative to the response generated from proliferating cells cultured
under identical conditions for 48 h. In the five dose study, serial 5 × 10-fold dilution from an initial
DMSO stock solution was performed, prior to incubation at each individual concentration (10 nM,
100 nM, 1 µM, 10 µM and 100 µM).
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Using seven absorbance measurements (time zero (Tz), control growth (C), and test growth in the
presence of drug at the five concentration levels (Ti)), the percentage growth was calculated at each of
the drug concentrations levels. Percentage growth inhibition was calculated as:
[(Ti−Tz)/(C−Tz)] × 100 for concentrations for which Ti ≥ Tz
[(Ti−Tz)/Tz] × 100 for concentrations for which Ti < Tz.
Three dose response parameters were calculated for each experimental agent. Growth inhibition
of 50% (GI50) was calculated from [(Ti−Tz)/(C−Tz)] × 100 = 50, which is the drug concentration
resulting in a 50% reduction in the net protein increase (as measured by Sulforhodamine B staining) in
control cells during the drug incubation. The drug concentration resulting in total growth inhibition
(TGI) was calculated from Ti = Tz. The LC50 (concentration of drug resulting in a 50% reduction in the
measured protein at the end of the drug treatment as compared to that at the beginning) indicating
a net loss of cells following treatment was calculated from [(Ti−Tz)/Tz] × 100 = −50. Values were
calculated for each of these three parameters if the level of activity was reached; however, if the effect
was not reached or was exceeded, the value for that parameter was expressed as greater or less than
the maximum or minimum concentration tested [36,37]. Data from one dose experiments pertains to
the percentage growth at 10 µM.
COMPARE analysis. COMPARE analysis was conducted using the private access system provided
by the National Cancer Institute (https://dtp.cancer.gov/databases_tools/compare.htm). Seed compounds
were analysed using a number of target sets: synthetic compounds, mechanistic set, standard agents,
marketed drugs and diversity set. While the minimum correlation was set to 0.4, correlations of less
than 0.5 were discounted. All other criteria were unchanged. Experiments that were carried out at
different concentrations to the seed compound were ignored unless the concentration deviated by ±0.1,
as was usual for older testing methods. COMPARE analysis was conducted solely on five dose data for
compounds 11 and 13 [38].
4. Conclusions
Novel ellipticines substituted at the 11-position are described and their activity evaluated against
topoisomerase II and cell growth in the National Cancer Institute’s 60 cell line screening platform.
Two of the novel compounds (13 and 16) show limited promise as topoisomerase II inhibitors at high
concentrations (>10 µM). On evaluation of anticancer effect at the NCI, compounds 11 and 13 show real
promise as future leads. Benzylamide 11 and unsaturated ketone 13 appear to have different modes of
action in their cellular effects with broad cytotoxicity seen for compound 13 but some selectivity of
cellular response seen for compound 11. COMPARE analysis identified a potential target for compound
11 in Aurora kinase due to correlation of 0.6 with the known inhibitor SCH1473759. This will be
investigated further in the future by synthesis of a series of ellipticine 11-amides to probe if this activity
can be tuned further.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/12/2/90/s1:
Figures S1–S3, 1H NMRs of relevant compounds; Figure S4, Three-fold dilution topoisomerase II inhibition assay
of compounds 13 and 16; Figures S5–S10, One dose NCI 60 cancer cell growth data (10 µM); Figures S11–S13, Five
dose NCI 60 cancer cell growth data with GI50, TGI and LC50 data for compound 11; Figures S14–S16, Five dose
NCI 60 cancer cell growth data with GI50, TGI and LC50 data for compound 13; Figure S17 COMPARE Analysis
data for compound 13 in direct comparison with SCH1473759 (NSC761691), an Aurora kinase inhibitor.
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Abbreviations
The following abbreviations are used in this manuscript:
AKT Protein Kinase B
CK2 Casein Kinase 2
GI50 Growth Inhibition 50%
LC50 Lethal concentration 50%
NCI National Cancer Institute
NSC numeric identifier for substances submitted to the National Cancer Institute (NCI)
Topo Topoisomerase
SAR Structure Activity Relationship
References
1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646–674. [CrossRef]
[PubMed]
2. Goodwin, S.; Smith, A.F.; Horning, E.C. Alkaloids of Ochrosia elliptica Labill. J. Am. Chem. Soc. 1959, 81,
1903–1908. [CrossRef]
3. Miller, C.M.; McCarthy, F.O. Isolation, biological activity and synthesis of the natural product ellipticine and
related pyridocarbazoles. R. Soc. Chem. Adv. 2012, 2, 8883–8918. [CrossRef]
4. O’Sullivan, E.C.; Miller, C.M.; Deane, F.M.; McCarthy, F.O. Emerging Targets in the Bioactivity of Ellipticines and
Derivatives. Studies in Natural Products Chemistry; Elsevier: Amsterdam, The Netherlands, 2013; pp. 189–232.
5. Paoletti, C.; Le Pecq, J.B.; Dat-Xuong, N.; Juret, P.; Garnier, H.; Amiel, J.L.; Rouesse, J. Antitumor activity,
pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials
of 2-methyl-9-hydroxy ellipticinium (NSC 264-137). Recent Results Cancer Res. 1980, 74, 107–123. [PubMed]
6. Ohashi, M.; Oki, T. Ellipticine and related anticancer agents. Expert Opin. Ther. Pat. 1996, 6, 1285–1294. [CrossRef]
7. Rouesse, J.; Spielmann, M.; Turpin, F.; Le Chevalier, T.; Azab, M.; Mondesir, J.M. Phase II study of elliptinium
acetate salvage treatment of advanced breast cancer. Eur. J. Cancer 1993, 6, 856–859. [CrossRef]
8. Monnot, M.; Mauffret, O.; Simon, V.; Lescot, E.; Psaume, B.; Saucier, J.M.; Charra, M.; Belehradek, J., Jr.;
Fermandjian, S. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode
binding model for ellipticine derivatives. J. Biol. Chem. 1991, 266, 1820–1829.
9. Froelich-Ammon, S.J.; Patchan, M.W.; Osheroff, N.; Thompson, R.B. Topoisomerase II binds to ellipticine in
the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.
J. Biol. Chem. 1995, 270, 14998–15004. [CrossRef]
10. Fossé, P.; René, B.; Charra, M.; Paoletti, C.; Saucier, J.M. Stimulation of topoisomerase II-mediated DNA
cleavage by ellipticine derivatives: structure-activity relationship. Mol. Pharmacol. 1992, 42, 590–595.
11. Poljakova, J.; Eckschlager, T.; Hrabeta, J.; Hrebackova, J.; Smutny, S.; Frei, E.; Martinek, V.; Kizek, R.;
Stiborova, M. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine
in human neuroblastoma cells. Biochem. Pharmacol. 2009, 77, 1466–1479. [CrossRef]
12. Vendôme, J.; Letard, S.; Martin, F.; Svinarchuk, F.; Dubreuil, P.; Auclair, C.; Le Bret, M. Molecular modelling of
wild-type and D816V c-kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine
kinases. J. Med. Chem. 2005, 48, 6194–6201. [CrossRef] [PubMed]
13. Prudent, R.; Vassal-Stermann, E.; Nguyen, C.-H.; Pillet, C.; Martinez, A.; Prunier, C.; Barette, C.; Soleilhac, E.;
Filhol, O.; Beghin, A. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic
growth. Cancer Res. 2012, 72, 4429–4439. [CrossRef] [PubMed]
14. Lu, C.; Wang, W.; El-Deiry, W.S. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in
p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol. Ther. 2008, 7, 2039–2046.
[CrossRef] [PubMed]
15. Andrews, W.J.; Panova, T.; Normand, C.; Gadal, O.; Tikhonova, I.G.; Panov, K.I. Old drug, new target:
ellipticines selectively inhibit RNA polymerase I transcription. J. Biol. Chem. 2013, 288, 4567–4582. [CrossRef]
[PubMed]
Pharmaceuticals 2019, 12, 90 14 of 15
16. Brown, R.V.; Wang, T.; Chappeta, V.R.; Wu, G.; Onel, B.; Chawla, R.; Quijada, H.; Camp, S.M.; Chiang, E.T.;
Lassiter, Q.R.; et al. The Consequences of Overlapping G-Quadruplexes and i-Motifs in the Platelet-Derived
Growth Factor Receptor β Core Promoter Nuclease Hypersensitive Element Can Explain the Unexpected
Effects of Mutations and Provide Opportunities for Selective Targeting of Both Structures by Small Molecules
To Downregulate Gene Expression. J. Am. Chem. Soc. 2017, 139, 7456–7475. [PubMed]
17. Miller, C.M.; O’Sullivan, E.C.; Devine, K.J.; McCarthy, F.O. Synthesis and biological evaluation of novel
isoellipticine derivatives and salts. Org. Biomol. Chem. 2012, 10, 7912–7921. [CrossRef]
18. Deane, F.M.; O’Sullivan, E.C.; Maguire, A.R.; Gilbert, J.; Sakoff, J.A.; McCluskey, A.; McCarthy, F.O. Synthesis
and evaluation of novel ellipticines as potential anti-cancer agents. Org. Biomol. Chem. 2013, 11, 1334–1344.
[CrossRef]
19. Russell, E.G.; O’Sullivan, E.C.; Miller, C.M.; Stanicka, J.; McCarthy, F.O.; Cotter, T.G. Ellipticine derivative
induces potent cytostatic effect in acute myeloid leukaemia cells. Investig. New Drugs 2014, 32, 1113–1122.
[CrossRef]
20. Russell, E.G.; Guo, J.; O’Sullivan, E.C.; O’Driscoll, C.M.; McCarthy, F.O.; Cotter, T.G. 7-formyl-10-methylisoellipticine,
a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic
activity in mice. Investig. New Drugs 2016, 34, 15–23. [CrossRef]
21. Kutney, J.P.; Noda, M.; Lewis, N.G.; Monteiro, B.; Mostowicz, D.; Worth, B.R. Dihydropyridines in synthesis
and biosynthesis. V. Synthesis of pyridocarbazole alkaloids: Olivacine and (±)-guantambuine. Can. J. Chem.
1982, 60, 2426–2430.
22. Mosher, C.W.; Crews, O.P.; Acton, E.M.; Goodman, L. Preparation and antitumor activity of olivacine and
some new analogs. J. Med. Chem. 1966, 9, 237–241. [CrossRef] [PubMed]
23. Schmidt, U.; Theumer, G.; Jäger, A.; Kataeva, O.; Wan, B.; Franzblau, S.G.; Knölker, H.-J. Synthesis and
Activity against Mycobacterium tuberculosis of Olivacine and Oxygenated Derivatives. Molecules 2018, 23,
1402. [CrossRef] [PubMed]
24. Awada, A.; Giacchetti, S.; Gerard, B.; Eftekhary, P.; Lucas, C.; de Valeriola, D.; Poullain, M.G.; Soudon, J.;
Dosquet, C.; Brillanceau, M.-H. Clinical phase I and pharmacokinetic study of S 16020, a new olivacine
derivative: report on three infusion schedules. Ann. Oncol. 2002, 13, 1925–1934. [CrossRef] [PubMed]
25. Thompson, D.; Miller, C.M.; McCarthy, F.O. Computer Simulations Reveal a Novel Nucleotide-type Binding
Orientation for Ellipticine-based Anticancer c-kit Kinase Inhibitors. Biochemistry 2008, 47, 10333–10344.
[CrossRef] [PubMed]
26. Gribble, G.W.; Saulnier, M.G.; Obaza-Nutaitis, J.A.; Ketcha, D.M. A versatile and efficient construction of the
6H-pyrido[4,3-b]carbazole ring system. Syntheses of the antitumor alkaloids ellipticine, 9-methoxyellipticine,
and olivacine, and their analogs. J. Org. Chem. 1992, 57, 5891–5899. [CrossRef]
27. Saulnier, M.G.; Gribble, G.W. An efficient synthesis of ellipticine. J. Org. Chem. 1982, 47, 2810–2812. [CrossRef]
28. Saulnier, M.G.; Gribble, G.W. Efficient construction of the 10H-pyrido[3,4-b]carbazole ring system. Syntheses
of isoellipticine and 7-methoxyisoellipticine. J. Org. Chem. 1983, 48, 2690–2695. [CrossRef]
29. Gribble, G.W.; Fletcher, G.L.; Ketcha, D.M.; Rajopadhye, M. Metalated heterocycles in the synthesis of
ellipticine analogs. A new route to the 10H-pyrido[2,3-b]carbazole ring system. J. Org. Chem. 1989, 54,
3264–3269. [CrossRef]
30. Modi, S.P.; Carey, J.J.; Archer, S. Synthesis of 5-methyl-6h-pyrido[4,3-b]carbazole-11-methanol. Tetrahedron
Lett. 1990, 31, 5845–5848. [CrossRef]
31. Modi, S.P.; Michael, M.A.; Archer, S.; Carey, J.J. An efficient synthesis of C-11 substituted 6H-pyrido[4,3-b]
carbazoles. Tetrahedron 1991, 47, 6539–6548. [CrossRef]
32. Plug, J.P.M.; Koomen, G.-J.; Pandit, U.K. An Expedient Synthesis of 9-Hydroxyellipticine. Synthesis 1992,
1992, 1221–1222. [CrossRef]
33. Domcke, S.; Sinha, R.; Levine, D.A.; Sander, C.; Schultz, N. Evaluating cell lines as tumour models by
comparison of genomic profiles. Nat. Commun. 2013, 4, 2126. [CrossRef] [PubMed]
34. Yu, T.; Tagat, J.R.; Kerekes, A.D.; Doll, R.J.; Zhang, Y.; Xiao, Y.; Esposite, S.; Belanger, D.B.; Curran, P.J.;
Mandal, A.K.; et al. Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the
Imidazo-[1,2-a]-Pyrazine Core. ACS Med. Chem. Lett. 2010, 1, 214–218. [CrossRef] [PubMed]
35. Pang, B.; Qiao, X.; Janssen, L.; Velds, A.; Groothuis, T.; Kerkhoven, R.; Nieuwland, M.; Ovaa, H.;
Rottenberg, S.; van Tellingen, O.; et al. Drug-induced histone eviction from open chromatin contributes to
the chemotherapeutic effects of doxorubicin. Nat. Commun. 2013, 4, 1908. [CrossRef] [PubMed]
Pharmaceuticals 2019, 12, 90 15 of 15
36. National Cancer Institute. Developmental Therapeutics Program. NCI-60 Human Tumour Cell Lines Screen.
Available online: https://dtp.cancer.gov/discovery_development/nci-60/default.htm (accessed on 14 May
2019).
37. Shoemaker, R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6,
813–823. [CrossRef]
38. Paull, K.D.; Shoemaker, R.H.; Hodes, L.; Monks, A.; Scudiero, D.A.; Rubinstein, L.; Plowman, J.; Boyd, M.R.
Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines:
Development of Mean Graph and COMPARE Algorithm. J. Natl. Cancer Inst. 1989, 81, 1088–1092. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
